So what is the recommended supportive care for patients starting amivantamab + lazertinib? 🔹 PO steroids to ⬇️ infusion reaction (days -2, -1, 0) 🔹 anticoagulation for VTE prophylaxis (first 4 mo) 🔹 oral doxycycline (wks 1-12) 🔹 clindamycin to scalp (wks 13+) 🔹 4%

LIVE from #GUTrends25 from Canary Islands🇪🇸 Our friends Uromigos ( Tom Powles & Brian Rini, MD ) Discuss Kidney Cancer Biomarkers (Brian's favourite Childhood memory). Join the Uromigos for a lively discussion beachfront🌴🌴 centering on the complexities of #KidneyCancer

The recommendations from Top Cancer Centers is mostly aligned with that of USPSTF for lung cancer but the story is completely different for prostate cancer. Why do you think that is? thelancet.com/journals/eclin…

🔊Thrilled to share our paper, just out in Annals of Oncology ESMO - Eur. Oncology We assessed the role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade response for patients with solid tumours. Proud to be part of this effort alongside a brilliant group of

Data exploring SABR in renal cancer to delay systemic therapy in selected patient looks promising & is being used ⬆️⬆️. Brian Rini, MD highlights the pateint selections means good outcomes will occur with surveillance. Randomisation with OS should be the endpoints . Trials awaited.

Deferred nephrectomy after ICI in mRCC—fresh data! 🔘Pathology showed 96% of specimens with necrosis, 21% of specimens showing no residual disease (pT0), and 21% exhibiting ≥95% necrosis. 🔘54% off systemic tx post-op 🔘Safe in selected patients ⚠️ Limitations: small cohort,

What if TCRs didn’t need to see peptides to bind MHC? A newly identified human TCR docks sideways onto HLA-DQ2.5—like an antibody. This could reshape how we think about antigen recognition 🧐🧐 Monash University Monash Medicine, Nursing and Health Sciences Rossjohn lab Nature Communications Congrats!

Because good science deserves great reporting. CONSORT 2025 is here: new checklist items ✅Focus on open science & data sharing ✅Stronger on patient involvement ✅Clearer, simpler, more aligned JAMA ASCO ESMO - Eur. Oncology EORTC European Association of Urology (EAU) OncoAlert LARVOL

GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC

New evidence today NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

🎖️Trainees in oncology and across all fields of medicine! Do not miss this manuscript on how to effectively respond to reviewer comments! Thanks Andrew Vickers Rod Dunn Christian Gratzke Morgan Roupret Alberto Briganti et al. European Urology Eur Urol Focus European Urology Oncology 🙏 OncoAlert

Online Now: Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts dlvr.it/TKMty0

Honored to welcome Prof. Silke Gillessen at our TSMO/ESMO Joint Symposium—insightful talk on new standards in mCRPC. Always enriching to share knowledge and perspectives! silke gillessen Advanced Prostate Cancer Consensus Conference OncoAlert ESMO - Eur. Oncology TTOD #prostatecancer

Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. ja.ma/42HMCWB

Congrats to Charles Swanton and team! 🎉 Tumor-Infiltrating Clonal Hematopoiesis isn’t just a passenger—it fuels cancer’s fire. ↗️Recurrence & death risk in NSCLC ➡️Rewires the tumor immune landscape 🩸🧬Aging blood, shaping cancer’s path. #Oncology #Cancer #Research #LungCancer

Organ preservation dream becoming reality! Neoadjuvant PD-1 blockade led to nonoperative management in 80% of early-stage dMMR solid tumors. 92% recurrence-free survival at 2 years. Surgery was not needed: dignity, function, and hope preserved. NEJM Mithat Gönen

🔬Not just mutations. 🧬Not just methylation. The new frontier in early cancer detection? The cfDNA fragmentome—size, shape, structure, and silence. nature International Society of Liquid Biopsy OncoAlert doi.org/10.1038/s41568…

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC

Shout out to our BSG Education article which includes esomeprazole and vonoprazan bsg.org.uk/web-education/…

🧪ctDNA in renal cell carcinoma: A Japan Nationwide Study ➡️Baseline high tumor fraction was associated with poor prognosis ➡️New mutations in serial ctDNA analysis showed poor prognosis 🩸ctDNA in RCC seems feasible to predict prognosis! OncoAlert IKCC Kidney Cancer International Society of Liquid Biopsy